Jazz Pharmaceuticals plc (JAZZ)
↓ Download CSV- Sector Manufacturing
- Incorporated L2
- Fiscal year ends Dec 31
In fiscal 2025, Jazz Pharmaceuticals plc reported revenue of $4.27B, up 4.9% from the prior year. The company ran a net loss, with a net margin of -8.3%.
Key ratios (FY2025)
-10.1%
Operating margin
-8.3%
Net margin
-8.2%
Return on equity
+4.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B |
| Operating Income | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M | $378.07M | $532.37M | $614.84M | $528.84M | $591.65M |
| Net Income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M | $238.62M | $523.37M | $447.10M | $487.85M | $396.83M |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B |
| Shareholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B |
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881.48M | $591.45M | $1.06B | $637.34M | $309.62M | $386.04M | $365.96M |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.51M | $899.65M | $776.40M | $798.90M | $693.09M | $592.39M |
| Capital Expenditures | $58.75M | $38.07M | $23.96M | $29.05M | $27.64M | $15.00M | $40.13M | $20.37M | — | — |
| Shares Outstanding | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M | 56.52M | 57.55M | 61.22M | 61.32M | 61.87M |